Clinicians are encouraged to integrate non-HDL-C and apo B measurements into routine practice, especially for patients with residual CV risk despite achieving LDL-C targets, or those with conditions, such as diabetes or hypertriglyceridemia, where LDL-C may inadequately reflect the true atherogenic burden. Here, APOB is linked to hypertriglyceridemia.